Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Final Trades: TSM, NXE, MRK & VWO
06:09pm, Friday, 11'th Nov 2022
The final trades of the week. With CNBC's Sara Eisen and the Fast Money traders, Courtney Garcia, Tim Seymour, Steve Grasso and Jeff Mills.
Here is Why Growth Investors Should Buy Merck (MRK) Now
05:45pm, Friday, 11'th Nov 2022 Zacks Investment Research
Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Innoviva (INVA) Right Now?
02:40pm, Friday, 11'th Nov 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Here is Why Growth Investors Should Buy Merck (MRK) Now
02:18pm, Friday, 11'th Nov 2022
Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Cheers Soft Inflation Data: 5 Growth Picks
12:59pm, Friday, 11'th Nov 2022 Zacks Investment Research
Invest in growth stocks like Murphy USA (MUSA), Merck (MRK) & New Fortress Energy (NFE), to name a few, as Wall Street rises on signs of cooling inflation.
Wall Street Cheers Soft Inflation Data: 5 Growth Picks
09:02am, Friday, 11'th Nov 2022
Invest in growth stocks like Murphy USA (MUSA), Merck (MRK) & New Fortress Energy (NFE), to name a few, as Wall Street rises on signs of cooling inflation.
Is A Fall Imminent For Merck Stock After A 12% Rise In A Month?
07:00am, Friday, 11'th Nov 2022
Going by historical performance, there is a meager chance of an increase in MRK stock over the next month.
AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up
03:20pm, Thursday, 10'th Nov 2022 Zacks Investment Research
AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.
Is Merck Too Dependent on Keytruda?
03:00pm, Wednesday, 09'th Nov 2022 The Motley Fool
The company's top-selling drug brought in the most revenue last quarter and was also its fastest-growing product.
Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat
02:47pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.
Final Trades: PayPal, Merck, Bristol Myers & more
02:29pm, Wednesday, 09'th Nov 2022
The "Halftime Report" traders give their top picks to watch for the second half.
Merck & Co., Inc. (MRK) Hit a 52 Week High, Can the Run Continue?
02:15pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Merck Too Dependent on Keytruda?
10:00am, Wednesday, 09'th Nov 2022
The company's top-selling drug brought in the most revenue last quarter and was also its fastest-growing product.
Election Day Is Here: Which Politicians Are Profiting (Or Losing) On Stocks?
07:37pm, Tuesday, 08'th Nov 2022 Benzinga
U.S. voters will spend the majority of Tuesday casting their ballots for the candidates they want to represent them in Congress, which consists of the House of Representatives and the Senate.
These el
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
04:17pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.
